| Literature DB >> 35168708 |
Patrick Reich1, Alexis Elward2.
Abstract
COVID-19 is a nonspecific viral illness caused by a novel coronavirus, SARS-CoV-2, and led to an ongoing global pandemic. Transmission is primarily human-to-human via contact with respiratory particles containing infectious virus. The risk of transmission to health care personnel is low with proper use of personal protective equipment, including gowns, gloves, N95 or surgical mask, and eye protection. Additional measures affecting the risk of transmission include physical distancing, hand hygiene, routine cleaning and disinfection, appropriate air handling and ventilation, and public health interventions such as universal masking and stay-at-home orders.Entities:
Keywords: COVID-19; Coronavirus; Epidemiology; Infection prevention; Personal protective equipment; Public health; SARS-CoV-2; Transmission
Mesh:
Year: 2022 PMID: 35168708 PMCID: PMC8837397 DOI: 10.1016/j.idc.2021.12.002
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN: 0891-5520 Impact factor: 5.982
Clinical manifestations of adult and pediatric patients with coronavirus disease 2019
| Manifestation | Pediatric, % | Adult, % |
|---|---|---|
| Asymptomatic | 16–19 | 17 |
| Fever | 44–57 | 69 |
| Cough | 33–44 | 53 |
| Dyspnea | 4–15 | 20 |
| Rhinorrhea | 13–16 | 13 |
| Diarrhea | 10–12 | 9 |
| Nausea/vomiting | 9–11 | 8 |
| Headache | 10–13 | 19 |
| Sore throat | 8–14 | 18 |
| Nasal congestion | 9 | 26 |
| Abdominal pain | 6–8 | Not reported |
| Fatigue | 6–9 | 31 |
| Myalgias | 5–14 | Not reported |
| Anosmia | 4 | 38 |
Severe acute respiratory syndrome coronavirus 2 attack rate in health care personnel
| Study | Dates | Setting | Sample Size | Attack Rate, % | Miscellaneous |
|---|---|---|---|---|---|
| Wang et al, | December 2019–March 2020 | China | 5442 | 2.2 | All enrolled and tested |
| Lai et al, | January–February 2020 | China | 9684 | 1.1 | 0.7% of 335 randomly selected asymptomatic HCP tested positive |
| Kluytmans-van den Bergh et al, | March 2020 | Netherlands | 9705 | 1 | 6.4% of 1353 tested due to development of symptoms tested positive |
| Clifton et al, | March–April 2020 | US army personnel | 336 | 1.7 | All enrolled and tested, 2 PCR+, 5 Ab+, 1 both+ |
| Fell et al, | March–July 2020 | US | 5374 | 7% | All with higher-risk exposures (household/workplace) |
| Self et al, | April–June 2020 | US seroprevalence study | 3248 | 6 | All enrolled and tested (serology) |
| Shah et al, | May–November 2020 | United States | 345 | 2.3 | All with significant occupational exposure to a COVID-19 patient |
| Koh et al, | January–July 2020 | China, United States, Germany, India, Japan, Singapore, Switzerland | 4163 | 0.7 | Systematic review and meta-analysis of 18 studies |
Abbreviations: Ab, antibody; COVID-19, coronavirus disease 2019; HCP, health care provider; PCR, polymerase chain reaction.
Pre-procedural testing
| Study | Dates | Setting/Population | Sample Size (Patients) | Percent Positivity, % | Miscellaneous |
|---|---|---|---|---|---|
| Lin et al, | March–April 2020 | US/Pediatric pre-procedural testing | 1295 | 0.9 | Range of 0.2% to 2.7% across 3 hospitals |
| Otto et al, | March–June 2020 | US/Pediatric pre-procedural and pre-admission testing | 1410 | 3.8 | |
| Aslam et al, | March–August 2020 | US/Cancer center pre-procedural testing | 11,540 | 0.6 | Fell below 0.3% after April 2020 |
| Bence et al, | March–October 2020 | US/Pediatric pre-procedural testing | 11,150 | 1.4 | |
| Haidar et al, | April–June 2020 | US/Pre-procedural testing | 10,539 | 0.1 | |
| Bowyer et al, | May–June 2020 | US/Ambulatory pre-procedural testing before endoscopy | 1000 | 0.8 | |
| Larsen et al, | May–July 2020 | US/Ambulatory pre-procedural testing | 3709 | 1 | |
| Tande et al, | December 2020–February 2021 | US/Pre-procedural testing | 39,156 | 3.1 |